Conditions: Adenoid Cystic Carcinoma; Squamous Cell Carcinoma; Sinonasal Carcinoma; Sinonasal Undifferentiated Carcinoma
Interventions: Radiation: Proton radiation therapy; Radiation: Intensity-modulated radiotherapy
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified April 2012
Feeds
4445 items (4445 unread) in 80 feeds
Acinar Cell Carcinoma
(28 unread)
Acinic Cell Carcinoma
(32 unread)
Adenoid Cystic Carcinoma
(54 unread)
Adrenal Gland Cancer
(324 unread)
Ampulla Of Vater
(13 unread)
Anal Cancer
(250 unread)
Angiosarcoma
(72 unread)
Appendix Cancer
(34 unread)
Bile Duct Cancer
(382 unread)
Brain and CNS
(1106 unread)
Carcinoid
(141 unread)
Endocrine/Neuroendocrine
(272 unread)
Gall Bladder Cancer
(219 unread)
Hemangioendothelioma
(23 unread)
Hepatoblastoma
(30 unread)
Pancreas
(45 unread)
Phyllodes
(18 unread)
PMP and Mucinous Tumors
(16 unread)
Rhabdomyosarcoma
(180 unread)
Sarcoma
(545 unread)
Twitter Pals
(661 unread)
Trial - Adenoid Cystic Carcinoma (4 unread)
-
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
Posted: October 21st, 2011, 8:00am MDT
-
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Posted: July 30th, 2007, 8:00am MDT
Condition: Head and Neck Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Completed - verified April 2012 -
UCN-01 and Irinotecan in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple-Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Posted: March 8th, 2002, 8:00am MST
Condition: Cancer
Interventions: Drug: 7-hydroxystaurosporine; Drug: irinotecan hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Virginia; National Cancer Institute (NCI); Washington University Siteman Cancer Center
Completed - verified August 2009 -
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
Posted: June 6th, 2001, 8:00am MDT
Conditions: Head and Neck Cancer; Oral Complications; Radiation Toxicity
Intervention: Drug: cevimeline hydrochloride
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Completed - verified May 2012